PY1934080A - Derivados de neuroesteroides y usos de estos.- - Google Patents
Derivados de neuroesteroides y usos de estos.-Info
- Publication number
- PY1934080A PY1934080A PY201901934080A PY1934080A PY1934080A PY 1934080 A PY1934080 A PY 1934080A PY 201901934080 A PY201901934080 A PY 201901934080A PY 1934080 A PY1934080 A PY 1934080A PY 1934080 A PY1934080 A PY 1934080A
- Authority
- PY
- Paraguay
- Prior art keywords
- hydrogen
- neurosteroid
- derived compounds
- derivatives
- functions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862667100P | 2018-05-04 | 2018-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PY1934080A true PY1934080A (es) | 2019-11-08 |
Family
ID=68384780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PY201901934080A PY1934080A (es) | 2018-05-04 | 2019-05-03 | Derivados de neuroesteroides y usos de estos.- |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190337975A1 (enExample) |
| EP (1) | EP3788055A4 (enExample) |
| JP (1) | JP2021523938A (enExample) |
| CN (1) | CN112823164A (enExample) |
| AR (1) | AR116659A1 (enExample) |
| AU (1) | AU2019264032A1 (enExample) |
| CA (1) | CA3099089A1 (enExample) |
| PY (1) | PY1934080A (enExample) |
| TW (1) | TW202014192A (enExample) |
| UY (1) | UY38213A (enExample) |
| WO (1) | WO2019211668A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| CN105579043B (zh) | 2013-08-23 | 2021-09-14 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物和其用途 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| MY190408A (en) | 2014-10-16 | 2022-04-21 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| US20170233433A1 (en) | 2014-10-16 | 2017-08-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| LT3250210T (lt) | 2015-01-26 | 2021-04-12 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti gydyti cns sutrikimus |
| PH12018501923B1 (en) | 2016-03-08 | 2024-06-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| CA3030420C (en) | 2016-07-11 | 2025-11-18 | Sage Therapeutics, Inc. | C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| JP7670626B2 (ja) | 2019-05-31 | 2025-04-30 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド及びその組成物 |
| JP7810970B2 (ja) * | 2020-02-05 | 2026-02-04 | シーポート・セラピューティクス・インコーポレイテッド | 神経ステロイドの脂質プロドラッグ |
| WO2021174205A1 (en) * | 2020-02-27 | 2021-09-02 | Brii Biosciences, Inc. | Prodrugs of neuroactive steroids |
| IL315509A (en) * | 2022-03-18 | 2024-11-01 | Marinus Pharmaceuticals Inc | Genaxolone medication matrims |
| CN119632996A (zh) * | 2024-12-06 | 2025-03-18 | 北京华睿鼎信科技有限公司 | 神经甾体衍生物固体分散体及制备方法和应用、中枢神经系统障碍相关病症的治疗药物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB748846A (en) * | 1953-10-28 | 1956-05-09 | Vitamins Ltd | A process for the manufacture of pregnan-3(-a)-ol-20-one and derivatives thereof |
| US5232917A (en) * | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| DK1038880T3 (da) * | 1994-02-14 | 2008-03-03 | Euro Celtique Sa | Androstaner og pregnaner til allosterisk modulering af GABA-receptor |
| WO2006010085A1 (en) * | 2004-07-09 | 2006-01-26 | Roxro Pharma, Inc. | Use of neurosteroids to treat neuropathic pain |
| WO2011120044A1 (en) * | 2010-03-26 | 2011-09-29 | Duke University | Conjugated neuroactive steroid compositions and methods of use |
| FR2973031B1 (fr) * | 2011-03-23 | 2013-11-29 | Univ Strasbourg | Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique |
| US20170022245A1 (en) * | 2013-11-26 | 2017-01-26 | Biopharma Works | Ganaxolone derivatives for treatment of central nervous systems disorders |
| AU2018290348B2 (en) * | 2017-06-23 | 2024-04-04 | Ayikoe-Guy MENSAH-NYAGAN | Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof |
| CN109666055A (zh) * | 2017-10-16 | 2019-04-23 | 张家口华健致远生物科技有限公司 | 调节中枢神经治疗抑郁症的化合物及其用途 |
-
2019
- 2019-05-03 UY UY38213A patent/UY38213A/es unknown
- 2019-05-03 CN CN201980033110.9A patent/CN112823164A/zh active Pending
- 2019-05-03 TW TW108115447A patent/TW202014192A/zh unknown
- 2019-05-03 AU AU2019264032A patent/AU2019264032A1/en not_active Abandoned
- 2019-05-03 US US16/403,100 patent/US20190337975A1/en not_active Abandoned
- 2019-05-03 PY PY201901934080A patent/PY1934080A/es unknown
- 2019-05-03 CA CA3099089A patent/CA3099089A1/en active Pending
- 2019-05-03 AR ARP190101187A patent/AR116659A1/es not_active Application Discontinuation
- 2019-05-03 EP EP19796480.2A patent/EP3788055A4/en not_active Withdrawn
- 2019-05-03 WO PCT/IB2019/000517 patent/WO2019211668A2/en not_active Ceased
- 2019-05-03 JP JP2021510564A patent/JP2021523938A/ja active Pending
-
2021
- 2021-08-02 US US17/392,004 patent/US20210363173A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20190337975A1 (en) | 2019-11-07 |
| AR116659A1 (es) | 2021-06-02 |
| TW202014192A (zh) | 2020-04-16 |
| EP3788055A4 (en) | 2022-03-30 |
| UY38213A (es) | 2019-10-31 |
| JP2021523938A (ja) | 2021-09-09 |
| EP3788055A2 (en) | 2021-03-10 |
| US20210363173A1 (en) | 2021-11-25 |
| AU2019264032A1 (en) | 2020-12-03 |
| CN112823164A (zh) | 2021-05-18 |
| CA3099089A1 (en) | 2019-11-07 |
| WO2019211668A2 (en) | 2019-11-07 |
| WO2019211668A3 (en) | 2019-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR116659A1 (es) | Derivados de neuroesteroides y usos de estos | |
| ES2564179T3 (es) | Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales | |
| MX373622B (es) | Mezclas de compuestos, su preparación y sus usos. | |
| CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| MX382160B (es) | Alquil glicosidos como surfactantes. | |
| DOP2016000145A (es) | Reguladores de nrf2 | |
| BR112018067383A2 (pt) | composição de aditivo de resina, composição de resina termoplástica e artigo moldado da mesma | |
| CL2017000863A1 (es) | Composición de activo de suavizante de tejidos | |
| BR112015026513A2 (pt) | derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares | |
| BR112017011387A2 (pt) | uso de compostos, e, composição cosmética. | |
| BR112014006482A8 (pt) | Uso de derivados de isossorbida para produção de preparações cosméticas | |
| DK2029711T3 (da) | Præparat, som indeholder en blanding af mono-, di-, og triglycerider og glycerin | |
| DOP2016000277A (es) | Triterpenoides con actividad inhibidora de la maduración del vih | |
| BRPI0921303B8 (pt) | Agente redutor de rugas, composto, e, preparação externa para a pele. | |
| BR112015021471A2 (pt) | compostos acilaminocicloalquila adequados para o tratamento de distúrbios que respondem à modulação do receptor de dopamina d3 | |
| BR112018015257A2 (pt) | composição para formação de alfa-gel e uma composição de alfa-gel | |
| EA201390939A1 (ru) | Новое замещенное производное изохинолина | |
| MX2020006945A (es) | Reaccion de prins y compuestos utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos. | |
| MX2019007670A (es) | Nuevos antioxidantes para cosmeticos y composiciones farmaceuticas que contienen eteres alquilicos de glicerol. | |
| MA42781B1 (fr) | Composés étheramines et leur utilisation en tant que collecteur de flottation | |
| ES2548521T3 (es) | Agentes odorantes con bajo contenido de azufre y estabilidad mejorada | |
| BR112018070981A2 (pt) | ésteres à base de carité inodoros | |
| BR112016022047A2 (pt) | Mistura de eteraminas, processo para fabricação de uma eteramina, e, uso de uma mistura de eteraminas | |
| MX2016015515A (es) | Aducto de monogicidil eter de maltodextrina. | |
| AR082775A1 (es) | Formulaciones de fumarato |